{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-009474","form_type":"8-K","ticker":"NXGL","cik":"0001468929","company_name":"NEXGEL, INC.","filed_at":"2026-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.137384+00:00","generated_at":"2026-05-15T15:53:27.113383+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"NEXGEL signs $35M deal to buy Celularity's biomaterial portfolio; expects revenue to triple to ~$35M","bullets":["Consideration up to $35M: $15M upfront plus $20M in milestone payments tied to net sales.","Deal expected to triple annual revenue to ~$35M and make NEXGEL immediately profitable upon closing.","Acquisition includes 6 commercial-stage regenerative products with existing reimbursement, plus 3 planned 510(k) filings through 2028.","Experienced commercial and scientific team from Celularity is expected to join NEXGEL, expanding sales reach.","NEXGEL also disclosed discussions for a $100M equity line of credit facility with a third-party investor."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-009474","json":"https://secwatch.observer/filing/0001493152-26-009474.json","markdown":"https://secwatch.observer/filing/0001493152-26-009474.md","text":"https://secwatch.observer/filing/0001493152-26-009474.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1468929/000149315226009474/0001493152-26-009474-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1468929/000149315226009474/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T15:53:27.113383+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4ec0bce79702bbd3a9520dc097751c461d692206","claim":"NEXGEL, INC. entered into Agreement with Celularity, Inc. valued at up to $35.0 million in cash, subject to certain adjustments, which will include (i) a $15.0 million (effective 2026-03-06).","evidence_excerpt":"On March 6, 2026, NexGel, Inc., a Delaware corporation (the “ Company ”), entered into an Asset Purchase and Exclusive License Agreement (the “ Agreement ”) with Celularity, Inc., a Delaware corporation (the “ Licensor ”), whereby the Licensor granted to the Company an exclusive license to its commercial-stage biomaterials portfolio and certain development-stage programs as more fully described in the Agreement and the Licensor agreed to sell to the Company assets related to the portfolio (collectively, the “ Business ”). Consideration for the Business will consist of up to $35.0 million in cash, subject to certain adjustments, which will include (i) a $15.0 million upfront payment and (ii) an additional $20.0 million in potential milestone payments based on net sales targets related to the Business.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1468929/000149315226009474/0001493152-26-009474-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Celularity, Inc."},{"label":"Value","value":"up to $35.0 million in cash, subject to certain adjustments, which will include (i) a $15.0 million"},{"label":"Effective","value":"2026-03-06"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}